Document:

EX-4.2

 Exhibit 4.2 

FIRST SUPPLEMENTAL INDENTURE 

FIRST SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of February 14, 2017, by and among ALERIS
INTERNATIONAL, INC., a Delaware corporation (the “Company”), ALERIS CORPORATION, a Delaware corporation (“Parent”), certain of the Company’s direct and indirect domestic Subsidiaries party hereto (together with
Parent, the “Guarantors”) and U.S. BANK NATIONAL ASSOCIATION, as trustee (in such capacity, the “Trustee”) and collateral agent (in such capacity, the “Collateral Agent”). 

W I T N E S S E T H: 

WHEREAS, the Company, the Guarantors, the Trustee and the Collateral Agent have heretofore executed and delivered an indenture, dated as of
April 4, 2016 (as amended or supplemented from time to time, the “Indenture”), providing for the issuance of 9.500% Senior Secured Notes due 2021; 

WHEREAS, pursuant to and on the date of the Indenture, the Company initially issued $550,000,000 aggregate principal amount of its 9.500%
Senior Secured Notes due 2021 (the “Initial Notes”); 
 WHEREAS, Sections 202 and 312 of the Indenture provide that the
Company may, from time to time and in accordance therewith, issue Additional Notes under the Indenture; 
 WHEREAS, the Company wishes to
issue an additional $250,000,000 aggregate principal amount of its 9.500% Senior Secured Notes due 2021 as Additional Notes (the “New Notes”); 

WHEREAS, Section 901 of the Indenture provides that, among other things, without the consent of any Holder, the Company, the Guarantors,
the Trustee and the Collateral Agent may enter into one or more indentures supplemental to the Indenture to provide for the issuance of Additional Notes in accordance with the terms of the Indenture; 

WHEREAS, pursuant to Section 901 of the Indenture, the Trustee and Collateral Agent are authorized to execute and deliver this
Supplemental Indenture; and 
 Whereas, the Company has requested that the Trustee and Collateral Agent execute and deliver this
Supplemental Indenture; 
 NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of
which is hereby acknowledged, the Company, the Guarantors, the Trustee and the Collateral Agent mutually covenant and agree for the equal and ratable benefit of the Holders of the Notes as follows: 

ARTICLE I 
 DEFINITIONS 

SECTION 1.1. Defined Terms. Capitalized terms used herein without definition shall have the meanings assigned to them in the Indenture.
The words “herein,” “hereof” and “hereby” and other words of similar import used in this Supplemental Indenture refer to this Supplemental Indenture as a whole and not to any particular section hereof. 

 ARTICLE II 

NEW NOTES 
 SECTION 2.1. Amount
of New Notes. The aggregate principal amount of New Notes to be authenticated and delivered under this Supplemental Indenture on February 14, 2017 is $250,000,000. 

SECTION 2.2. Terms of New Notes. Provisions relating to the New Notes are set forth in the Appendix, which is hereby incorporated in,
and expressly made a part of, this Supplemental Indenture mutatis mutandis. The New Notes are to be issued as Additional Notes under the Indenture and shall: 
  

	 	(a)	be issued as part of the existing series of Initial Notes under the Indenture, and the New Notes and the Initial Notes shall be treated as a single class for all purposes under the Indenture; 

 

	 	(b)	have identical terms and conditions to the Initial Notes except that the New Notes shall (i) be issued on February 14, 2017, (ii) be issued at a purchase price of 107.000% of the principal amount plus accrued
interest deemed to have accrued from October 1, 2016 and (iii) have a first interest payment date of April 1, 2017; 

  

	 	(c)	be issuable in whole in the form of one or more Global Notes to be held by the Depository and substantially in the form, including appropriate transfer restriction legends, provided in Exhibit 1 to the Appendix; and

  

	 	(d)	initially bear, in the case of New Notes sold under Rule 144A of the Securities Act, the CUSIP number of 014477 AR4 and ISIN of US014477AR46, and, in the case of New Notes sold under Regulation S of the Securities Act,
the CUSIP number of U01484 AH4 and ISIN of USU01484AH49. 

 ARTICLE III 

MISCELLANEOUS 
 SECTION 3.1.
Notices. All notices and other communications to the Company or the Guarantors shall be given as provided in the Indenture. 

SECTION 3.2. Parties. Nothing expressed or mentioned herein is intended or shall be construed to give any Person, other than the
Holders, the Trustee and the Collateral Agent, any legal or equitable right, remedy or claim under or in respect of this Supplemental Indenture or the Indenture or any provision herein or therein contained. 

SECTION 3.3. GOVERNING LAW. THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE
OF NEW YORK. 
 SECTION 3.4. Severability. In case any provision in this Supplemental Indenture shall be invalid, illegal or
unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and such provision shall be ineffective only to the extent of such invalidity, illegality or unenforceability.

 SECTION 3.5. Benefits Acknowledged. Each of the Company and the Guarantors acknowledge that it will receive direct and indirect
benefits from the financing arrangements contemplated by this Supplemental Indenture and that the covenants, guarantees and waivers made by it, as applicable, pursuant to the Indenture and/or this Supplemental Indenture have been knowingly made in
contemplation of such benefits. The Notes Guarantees of the Guarantors are subject to the terms and conditions set forth in the Indenture. 

 SECTION 3.6. Ratification of Indenture; Supplemental Indentures Part of Indenture. Except
as expressly amended hereby, the Indenture and each Notes Guarantee is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect. This Supplemental Indenture shall form a part
of the Indenture for all purposes, and every Holder of Notes heretofore or hereafter authenticated and delivered shall be bound hereby. 

SECTION 3.7. Acknowledgment and Affirmation. The Company and each Guarantor hereby expressly acknowledge, as of the date hereof,
(i) all of its obligations under the Security Documents to which it is a party are reaffirmed and remain in full force and effect on a continuous basis, (ii) its grant of security interests pursuant to the Security Documents are reaffirmed
and remain in full force and effect after giving effect to the issuance of the New Notes, (iii) the Secured Obligations (as defined in the Security Agreement) include, among other things and without limitation, the due and punctual payment of
the principal of, interest on, and premium (if any) on, the Notes and (iv) except as expressly set forth herein, the execution of this Supplemental Indenture shall not serve to effect a novation of the Secured Obligations (as defined in the
Security Agreement). 
 SECTION 3.8. The Trustee and the Collateral Agent. The Trustee and the Collateral Agent shall not be
responsible in any manner whatsoever for or in respect of the validity or sufficiency of this Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made solely by the Company and the Guarantors. 

SECTION 3.9. Counterparts. The parties may sign any number of copies of this Supplemental Indenture. Each signed copy shall be an
original, but all of them together represent the same agreement. The exchange of copies of this Supplemental Indenture and of signature pages by facsimile, .pdf transmission or other electronic means shall constitute effective execution and delivery
of this Supplemental Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or .pdf transmission or other electronic means shall be deemed to be their original signatures for all purposes. 

SECTION 3.10. Headings. The Section and Article headings herein are for convenience only and shall not affect the construction hereof.

 [Signature Pages Follow] 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly
executed as of the date and year first above written. 
  

					
	ALERIS INTERNATIONAL, INC.
		
	By:	 	 /s/ Eric M. Rychel

		 	Name:	 	Eric M. Rychel
		 	Title:	 	Executive Vice President, Chief Financial Officer and Treasurer
	
	ALERIS CORPORATION
		
	By:	 	 /s/ Eric M. Rychel

		 	Name:	 	Eric M. Rychel
		 	Title:	 	Executive Vice President, Chief Financial Officer and Treasurer
	
	ALERIS ROLLED PRODUCTS, INC.
	ALERIS ROLLED PRODUCTS, LLC
	ALERIS ROLLED PRODUCTS SALES CORPORATION
	IMCO RECYCLING OF OHIO, LLC
	ALERIS OHIO MANAGEMENT, INC.
	NICHOLS ALUMINUM LLC
		
	By:	 	 /s/ Eric M. Rychel

		 	Name:	 	Eric M. Rychel
		 	Title:	 	President

 
					
	U.S. BANK NATIONAL ASSOCIATION,
	as Trustee and Collateral Agent
		
	By:	 	 /s/ James Kowalski

		 	Name:	 	James Kowalski
		 	Title:	 	Vice PresidentEX-4.1

 Exhibit 4.1 

EXECUTION VERSION 

SUPPLEMENTAL INDENTURE, dated as of February 16, 2017, between ARIAD Pharmaceuticals, Inc., a Delaware corporation, as issuer (the
“Company”), and Wells Fargo Bank, National Association, a national banking association, as trustee (the “Trustee”), to the Indenture, dated as of June 17, 2014 between such parties (the “Indenture”). All references
to the “Indenture” shall be to the Indenture and, as applicable, this Supplemental Indenture. All capitalized terms used but not defined herein shall have the meanings specified in the Indenture. 

RECITALS 
 WHEREAS, the Company,
the issuer of the Notes under the Indenture, and the Trustee have heretofore executed and delivered the Indenture; 
 WHEREAS, through a
merger (the “Merger”) contemplated by a merger agreement, dated as of January 8, 2017 (as amended, the “Merger Agreement”), among the Company, Takeda Pharmaceutical Company Limited (the
“Parent”), a corporation organized under the laws of Japan, and Kiku Merger Co., Inc., (the “Purchaser”), a Delaware corporation and an indirect, wholly-owned subsidiary of Parent, Purchaser has merged with and into
the Company, with the Company continuing as the surviving corporation in the Merger and becoming an indirect, wholly-owned subsidiary of Parent effective as of February 16, 2016 (the “Effective Date”); 

WHEREAS, the consummation of the Merger as contemplated by the Merger Agreement constitutes a Merger Event under the terms of the Indenture;

 WHEREAS, under Section 15.06(b) of the Indenture, at and after the effective time of a Merger Event, the right to convert each
$1,000 principal amount of Notes shall be changed to a right to convert such Notes into cash, the kind and amount of shares of stock, securities or other property or assets that a holder of a number of shares of Common Stock equal to the Conversion
Rate immediately prior to such transaction would have owned or been entitled to receive (the “Reference Property”); 

WHEREAS, under the terms of the Merger Agreement, as a result of the Merger, the Company’s Common Stock was converted into a right to
receive an amount in cash, without interest, equal to $24.00 per share of Common Stock; 
 WHEREAS, Section 15.06(a) of the Indenture
provides that, in connection with a Merger Event, the Company or the successor or purchasing Person, as the case may be, shall execute with the Trustee a supplemental indenture providing for the conversion and settlement of the Notes as set forth in
the Indenture and for adjustments, which shall be as nearly equivalent as may be practicable to the adjustments provided for in Article 15 of the Indenture; 

WHEREAS, the Company has concluded that the phrase “Section 11.01(b)” in Section 15.06 of the Indenture is defective and
inconsistent with the other provisions of the Indenture and the intent of the Issuer and the Trustee in negotiating the Indenture and should be deleted and replaced with the phrase “Section 11.01(b) and/or Section 11.01(i), as
applicable,”; 
 WHEREAS, this Supplemental Indenture has not resulted in a material modification of the Notes for Foreign Account Tax
Compliance Act (FATCA) purposes; 
 WHEREAS, all requirements necessary to make this Supplemental Indenture a valid, binding and enforceable
instrument in accordance with its terms have been done and performed, and the execution and delivery of this Supplemental Indenture has been duly authorized in all respects; 

NOW, THEREFORE, in consideration of the premises hereof, the parties have executed and delivered this Supplemental Indenture, and the Company
and the Trustee agree for the benefit of each other and for the equal and ratable benefit of the Noteholders, as follows: 

 AGREEMENT 

SECTION 1.    Capitalized Terms. 

Any capitalized term used and not otherwise defined herein shall have the meaning assigned to such term in the Indenture. 

SECTION 2.    Correction of a Defect. 

The phrase “Section 11.01(b)” in Section 15.06 of the Indenture is deleted and replaced with the phrase “Section 11.01(b)
and/or Section 11.01(i), as applicable,”. 
 SECTION 3.    Settlement upon Conversion. 

From and after the Effective Date, Noteholders shall have the right to convert the Notes (pursuant to, and subject to the conditions of, the
Indenture) solely into the Reference Property. For the avoidance of doubt, the “Reference Property” shall be equal to $2,580.228 (without interest) per $1,000 principal amount of Notes. However, if a conversion occurs on or after the date
the Company gives notice of the occurrence of the Effective Date applicable to the Merger, and on or prior to 5:00 p.m. New York City time on the Business Day immediately prior to the Fundamental Change Repurchase Date applicable to the Merger,
pursuant to Section 15.03 of the Indenture Noteholders shall be entitled to receive, upon conversion, $2,592.0216 (without interest) per $1,000 principal amount of Notes. For the avoidance of doubt, the Company shall pay the Reference Property
due in respect of each Conversion Obligation on the third Trading Day immediately following the relevant Conversion Date. 
 SECTION
4.    Notes. 
 Each Note, with effect on and from the Effective Date, shall be deemed supplemented, modified and
amended in such manner as necessary to make the terms of such Notes consistent with the terms of the Indenture, as amended by this Supplemental Indenture. 

SECTION 5.    Ratification and Effect. 

Except as hereby expressly amended, the Indenture is in all respects ratified and confirmed and all the terms, provisions and conditions
thereof shall be and remain in full force and effect. Upon and after the execution of this Supplemental Indenture, the Indenture shall be supplemented in accordance herewith, this Supplemental Indenture shall form a part of the Indenture for all
purposes and each reference in the Indenture to the Indenture shall mean and be a reference to the Indenture as modified hereby. 
 SECTION
6.    Responsibility of the Trustee 
 The recitals in the Supplemental Indenture shall be taken as the statements of the
Company, and the Trustee assumes no responsibility for their correctness. The Trustee shall not be responsible or accountable in any manner whatsoever for or with respect to the validity or sufficiency of this Supplemental Indenture. The Trustee
shall be under no duty whatsoever to make any determination whether any execution, modification, amendment, supplement or confirmation to any document is necessary to implement such amendments and waivers, including those contained herein, and shall
be entitled to conclusively rely on the documentation required to be provided under the terms of the Indenture in a form reasonably satisfactory to the Trustee. 

SECTION 7.    Governing Law. 

This Supplemental Indenture shall be governed by and construed in accordance with the laws of the State of New York. 

 SECTION 8.    Conflicts. 

To the extent of any inconsistency between the terms of the Indenture or the Notes and this Supplemental Indenture, the terms of this
Supplemental Indenture will control. 
 SECTION 9.    Miscellaneous. 

This Supplemental Indenture constitutes the entire agreement of the parties hereto with respect to the amendments to the Indenture set forth
herein. All covenants and agreements in this Supplemental Indenture given by the parties hereto shall bind their successors. In case any provision in this Supplemental Indenture shall be invalid, illegal or unenforceable, the validity, legality and
enforceability of the remaining provisions hereof or of the Indenture shall not in any way be affected or impaired thereby. The section headings are for convenience only and shall not affect the construction hereof. The parties may sign any number
of copies of this Supplemental Indenture. Each signed copy shall be an original, but all of them together represent the same agreement, binding on the parties hereto. 

Signatures follow. 

 
			
	ISSUER:
	
	ARIAD PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Manmeet S. Soni

	Name:	 	Manmeet S. Soni
	Title:	 	 Executive Vice President, Chief
 Financial
Officer and Treasurer

	
	TRUSTEE:
	
	WELLS FARGO BANK, NATIONAL ASSOCIATION
		
	By:	 	 /s/ Stefan Victory

	Name:	 	Stefan Victory
	Title:	 	Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}]]